Indaptus Therapeutics (NASDAQ:INDP) Shares Down 7.7% – Time to Sell?

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) fell 7.7% on Friday. The company traded as low as $2.55 and last traded at $2.63. 496,216 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 609,792 shares. The stock had previously closed at $2.85.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

The business’s fifty day moving average price is $2.14 and its 200 day moving average price is $2.32. The stock has a market cap of $350.42 million, a P/E ratio of -0.42 and a beta of 0.97.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to stimulate the body’s innate and adaptive immune responses while limiting the toxicity associated with certain bacterial components.

Indaptus’ technology platform uses detoxified bacterial toxins, referred to as “DeTocs,” to activate immune cells. Its lead product candidate, Decoy20, is an investigational combination of detoxified toxins being developed as a potential treatment for solid tumors.